Taken together, we robustly characterized BRD4 as a progression‐associated metabolic driver for accurate prognostication in GIST and provided a rationale for dual blockade of KIT and BRD4 in GIST therapies. This evidence concerns the gene BRD4 and gastrointestinal stromal tumor.